Damora Therapeutics

Damora Therapeutics is a Waltham, Massachusetts-based biotechnology company focused on developing a new generation of disease-modifying subcutaneous biologics for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs). The company's pipeline targets two rare blood disorders Essential Thrombocythemia (ET), a chronic c... ondition causing excess platelet production, and Myelofibrosis (MF), a blood cancer in which bone marrow is replaced by scar tissue for which no currently available treatments address the underlying genetic cause. Its lead program, DMR-001, is a potentially best-in-class monoclonal antibody specifically targeting mutCALR, with additional pipeline candidates DMR-002 and DMR-003 designed to address the broader spectrum of mutCALR MPN patients. The company's pipeline was developed from assets originated by Paragon Therapeutics, and its leadership team brings deep experience from Blueprint Medicines, Arcus Biosciences, Medivation, and other leading life sciences organizations.Read More